Newsline

National Security , Newsline

COVID-19 Vaccine candidate from Pfizer and Biontech Shows Significant Success

Posted on Tuesday, November 10, 2020
|
by Outside Contributor
|
0 Comments
|
Print

pfizer NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

  • Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
  • Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
  • Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
  • Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
  • Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints.

You can read more from Pfizer here.

Share this article:
Subscribe
Notify of
guest
0 Comments
Most Voted
Newest Oldest
Inline Feedbacks
View all comments
jim nicholson and kamala harris with bible and rosary behind them about her anti-catholic acts
ActBlue logo
United States Treasury check and American flag. Concept of stimulus, economic recovery payment, tax refund. Federal government grant, loan, benefit and assistance
poland and germany flags on map with euros

Stay informed! Subscribe to our Daily Newsletter.

"*" indicates required fields

0
Would love your thoughts, please comment.x
()
x

Subscribe to AMAC Daily News and Games